Vista antagonist and methods of use
US-2016331803-A1 · Nov 17, 2016 · US
Vista modulators for diagnosis and treatment of cancer
US9890215B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9890215-B2 |
| Application number | US-201414158531-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 17, 2014 |
| Priority date | Jun 22, 2012 |
| Publication date | Feb 13, 2018 |
| Grant date | Feb 13, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure relates to compositions and therapeutic methods for activating an immune response in a patient in need thereof. In a preferred embodiment, the subject methods and compositions are able to antagonize the activity of VISTA, a naturally occurring “checkpoint” protein which contributes to immune tolerance, optionally in combination with an antagonist of a second checkpoint pathway such as PD-1. For example, such methods and compositions may be suitable for preventing and treating colon cancer or another cancer. An exemplary VISTA antagonist, specifically, an anti-VISTA antibody, is demonstrated herein to activate an immune response against cancer cells in vitro and in vivo, thereby conferring protective anti-tumor immunity which decreased tumor burden. Additionally, an additive benefit was observed when a VISTA antagonist was used in combination with a second checkpoint protein antagonist, specifically, an antibody against PD-1 ligand (PD-L1).
First claim
Opening claim text (preview).
What is claimed is: 1. A method for effecting a synergistic enhancement in CD8 + T cell immunity in a subject in need thereof comprising administering a synergistic combination comprising an antagonistic anti-VISTA antibody and a PD-1 antagonist, with the proviso that the condition to which CD8 + T cell immunity is enhanced does not comprise cancer. 2. The method of claim 1 , wherein the PD-1 antagonist is an antibody. 3. The method of claim 2 , wherein the PD-1 antagonist is an anti-PD-1 or anti-PD-L1 antibody. 4. The method of claim 1 wherein the anti-VISTA antibody and the PD-1 antagonist may be in the same or different compositions. 5. The method of claim 1 , wherein the synergistic combination consists of an anti-VISTA antibody and a PD-1 antagonist. 6. The method of claim 5 , wherein the PD-1 antagonist consists of an anti-PD-1 antibody. 7. The method of claim 1 , wherein the subject has an infection and the method results in a synergistic enhancement in CTL immunity against said infection. 8. The method of claim 7 , wherein the infection is caused by a virus.
Assignees
Inventors
Classifications
comprising antibodies · CPC title
- C07K16/2827Primary
against B7 molecules, e.g. CD80, CD86 · CPC title
Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title
B7 molecules, e.g. CD80, CD86 · CPC title
against the immunoglobulin superfamily · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9890215B2 cover?
- The present disclosure relates to compositions and therapeutic methods for activating an immune response in a patient in need thereof. In a preferred embodiment, the subject methods and compositions are able to antagonize the activity of VISTA, a naturally occurring “checkpoint” protein which contributes to immune tolerance, optionally in combination with an antagonist of a second checkpoint pa…
- Who is the assignee on this patent?
- King S College London, Dartmouth College
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2827. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).